Dr. Guy El Helou is a clinical assistant professor in the Division of Infectious Disease and Global Medicine. He takes care of patients who present with infectious complications mainly following solid organ transplantation. He has a special interest in cytomegalovirus, or CMV, fungal infections and nontuberculous mycobacteria.
Areas of Expertise (5)
Infections in Immunocompromised Patients
Infections in Transplant Recipients
Hepatitis C virus and kidney transplantation: Recent trends and paradigm shiftsTransplantation Reviews
Guy El Helou, ColleenJay and MarinaNunez
The management of HCV infection in kidney transplantation presents significant challenges. HCV, left untreated, worsens patient and graft survival after kidney transplantation through multiple mechanisms. The field has evolved significantly in recent years, due to the ability to effectively eliminate the virus with direct-acting antivirals. Limited data suggest that current HCV treatment improves outcomes of infected kidney transplant patients. Along with the ability to successfully treat HCV, the increased HCV prevalence among donors has led to transplantation of kidneys from HCV-viremic donors into uninfected recipients. The practice has become increasingly common, but optimization of protocols to guide this practice is currently under debate.
Absolute lymphocyte count as marker of cytomegalovirus and allograft rejection: Is there a “Safe Corridor” after kidney transplantation?Transplant Infectious Disease
Guy El Helou, Brian Lahr and Raymund Razonable
The contrasting outcomes of lymphocyte manipulation after solid organ transplantation are allograft rejection and infections, commonly with cytomegalovirus (CMV). Peripheral blood absolute lymphocyte count (ALC) may serve as a predictive marker for these outcomes. Using a retrospective review of clinical and laboratory dataset, we aimed to determine whether a range of ALC (termed “safe ALC corridor”) exists where CMV infection and rejection outcomes are minimal in a cohort of 381 kidney transplant recipients.
Retrograde Parotid Gland Infusion through Stensen's Duct in a Non-Human Primate for Vectored Gene DeliveryImmunology and Infection
Guy El Helou, et al.
Salivary glands are an attractive tissue target for gene therapy with promising results already leading to human trials. They are inherently capable of secreting proteins into the bloodstream and are easily accessible, making them potentially superior tissue sites for replacement hormone production or vaccination by gene transfer. Suggested methods for gene delivery include transcutaneous injection and retrograde infusion through salivary ducts. We demonstrate how to perform Retrograde Salivary Gland Infusion (RSGI) in non-human primates. We describe the important anatomic landmarks including identification of the parotid papilla, an atraumatic method of cannulating and sealing Stensen's Duct utilizing basic dental tools, polyethylene tubing, and cyanoacrylate, and the appropriate rate of infusion.